Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Shares of Johnson & Johnson dipped 0.7% on Friday to $204.39 following the company's announcement of a deal with the Trump administration to lower U.S. drug prices. In return, J&J secured exemptions from certain U.S. tariffs. The company said it will offer medicines at discounted rates via TrumpRx.gov and match Medicaid pricing levels seen in other developed countries, though it did not specify which drugs would be involved or the exact discount sizes. The administration made similar deals with nine other pharmaceutical firms in December as part of its effort to close the gap that leaves U.S. patients paying nearly three times more than those abroad.

Johnson & Johnson shares fell 0.7% on Friday, closing at $204.39. The company said it reached an agreement with the U.S. government to lower drug prices in exchange for exemptions from tariffs.

Johnson & Johnson shares slipped about 0.5% to $204.76 on Friday after the company said it struck an agreement with President Donald Trump’s administration to lower drug prices for Americans in return for exemptions from U.S. tariffs. Johnson & Johnson did not say which medicines are included or how large the price cuts would be.

Johnson & Johnson shares closed up 0.23% on Tuesday after the company announced fresh clinical and regulatory updates across oncology and immunology.

Johnson & Johnson shares eked out a 0.02% gain to $206.95 on Wednesday, a rare green finish as U.S. stocks slipped in the final session of 2025. The S&P 500 fell 0.74% and the Dow lost 0.63%. MarketWatch